Thomas P. Reeves joined Interface Biologics in November of 2008 as President and Chief Executive Officer. Tom brings a wealth of experience in running different companies in a variety of industries through various stages of growth. Most recently, he was President and COO of Occulogix, Inc. (NASDAQ: OCCX) a medical device company where he was instrumental in their Initial Public Offering raising over $100 million. Prior to OccuLogix, Mr. Reeves was the President of Borderfree, an international e-commerce service provider which was sold to Canada Post in 2004. Mr Reeves has also led Beamscope Canada Inc., Merisel Canada, Merisel Europe, and Merisel’s UK operation. Mr. Reeves started his career with the Boston Consulting Group (BCG) in San Francisco. He holds a BA in Economics, magna cum laude, from Harvard University and an MA in International Relations from the Australian National University.
Kevin comes to Interface Biologics Inc. with over fifteen (15) years of Canadian and international management experience in finance and operations primarily with life sciences and medical device companies. Prior to joining IBI, Kevin worked as Director, Finance & Controller at St. Jude Medical Canada, Inc., a subsidiary of this multi-billion dollar publicly traded medical device manufacturer (NYSE: SJT). Prior to SJT, he was Director, Finance & Controller at Affinum Pharmaceuticals, Inc., an early stage biotech company focused on the development and commercialization of novel anti-infective compounds. Kevin has also held senior Finance positions at Fresenius Medical Care Canada, Inc. (NASDAQ: FMS) and Boston Scientific Corporation (NYSE: BSC) at their headquarters in Massachusetts. Kevin started his career at Deloitte & Touche and is a Chartered Accountant and a B.Comm graduate of the University of Toronto.
Dr. Esfand has been a member of staff at Interface Biologics since September, 2003, leading the Kinesyx development team. Prior to joining Interface Biologics, Roseita spent over seven years at DNT Inc. (USA), where she developed a variety of technologies in polymer drug delivery, focusing on viral and cancer therapy. She worked closely with regulatory authorities for submission and approval of novel polymeric systems. Her experience in developing technologies led to her transfer to PanBio Ltd. (Australia), for replacing traditional gold visualization techniques with novel polymers in the diagnostic area. Roseita was also assigned to Starpharma Ltd. (Australia), working on polyvalent polymers as nanotechnology platforms for viral and cancer therapy. She was successful in transferring technologies to both companies. Roseita is a member of the executive team of the CIC, a coalition of scientists that develops and advocates public policy positions on scientific issues. Roseita has a Ph.D in Pharmaceutical Sciences from the University of Kent, UK. Prior to leaving the United Kingdom she spent time working at SmithKline Beecham.
Ms. Ho is a charter member of the Interface Biologics scientific team. During her tenure, she has served as Director of Research and Development, Quality Assurance Manager and currently leads the Endexo™ development team. Jeanette was involved in developing Endexo™ technology during her graduate studies at University of Toronto. At that time, she was also President and CEO of Jycho Surface Technologies, Inc., the company that began the scale-up and commercialization of the Endexo™ technology. She brings expertise in surface modifying macro-molecule (SMM) technology, polymer development and characterization, industrial processing and device manufacturing. Jeanette holds a B.A.Sc. in Chemical Engineering from Waterloo University and an M.A.Sc. from University of Toronto.
Dr. Santerre founded Interface Biologics Inc. in 2001 to develop improved medical implants based on his innovative research in polymer chemistry. Dr. Santerre is responsible for the strategic direction of research and development at Interface. Previously, Dr. Santerre was the manager of the materials development laboratory at the University of Ottawa and developed technology for the Ottawa Heart Institute artificial heart (World Heart Corporation). He is currently a full professor of biomaterials with appointments at the Faculty of Dentistry and the Institute for Biomaterials and Biomedical Engineering at the University of Toronto. He is an expert in the areas of physical, surface and biological characterization of polymers, polymer synthesis, material biocompatibility, drug polymers, and medical device manufacturing.
Mark coordinated the formation of the company in December 2001. He negotiated licensing terms with the University of Toronto, prepared the terms of the seed capital funding, and organized the company for operations beginning in January 2002. Mark is responsible for managing the financing and business aspects of the corporation. He raised $12M in seed capital for the corporation. He has taken the staff of Interface from 0 to 15 people and helped recruit the senior management team. Mr. Steedman was instrumental in landing early deals with several large medical device manufacturers, and oversaw company operations from early R&D to its first revenues in 2004. Mark holds degrees in Applied Science in Engineering, a Bachelor of Arts in Biology both from Queen’s University and an MBA from Wilfrid Laurier University.